银休特 PODD 深 沪
等待开盘 10-08 09:30:00 美东时间
134.36
-0.370
-0.27%
华盛通- 最 高137.10
- 今 开134.94
- 成交量 103.29万股
- 最 低 133.33
- 昨 收 134.73
- 总市值 93.18亿
- 52周最高 354.88
- 市盈率 静 38.62
- 换手率 1.49%
- 52周最低 126.40
- 委 比 87.62%
- 总股本 6935.42万
- 历史最高 354.88
- 量 比 0.45
- 振 幅 2.80%
- 历史最低 14.00
- 每 手 1
- 风险率 68.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Barclays Initiates Coverage On Insulet with Equal-Weight Rating, Announces Price Target of $150
Barclays analyst Christopher Pasquale initiates coverage on Insulet (NASDAQ:PODD) with a Equal-Weight rating and announces Price Target of $150.
10-07 20:49
Moderna, Illumina lead healthcare gains in September as medtech drags
Healthcare stocks underperformed the broader market in September, with the Health Care Select Sector SPDR Fund (XLV) falling 1.89% while the SPDR S&P 500 ETF Trust (SPY) gained 0.27%. The sector's wea...
10-03 23:05
Insulet Amends Credit Facilities, Expands Revolving Commitments
Insulet ( ($PODD) ) has provided an announcement. On September 21, 2026, Insule...
09-22 05:27
Kestra Appoints Curtis Kopf as Senior Vice President of Customer Experience
Kestra Medical Technologies appointed Curtis Kopf as Senior Vice President of Customer Experience to enhance patient journey and support for the ASSURE® WCD. With extensive experience in customer experience and digital transformation, Kopf will lead end-to-end patient support, leveraging data and automation. Kestra is investing in AI initiatives to strengthen its commercial capabilities and drive growth.
08-26 10:00
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
These Analysts Slash Their Forecasts On Insulet After Q2 Results
Insulet Corp. (NASDAQ:PODD) on Wednesday posted upbeat second-quarter results but lowered its full-year revenue guidance. Adjusted earnings rose to $1.66 per share from $1.17 a year earlier, beating the analyst consensus estimate of $1.45. Revenue increased 23.5% year over year to $801.7 million, to...
08-06 19:28
BTIG Downgrades Insulet to Neutral
BTIG analyst Marie Thibault downgrades Insulet (NASDAQ:PODD) from Buy to Neutral.
08-06 18:05
Truist Securities Downgrades Insulet to Hold, Lowers Price Target to $153
Truist Securities analyst Richard Newitter downgrades Insulet (NASDAQ:PODD) from Buy to Hold and lowers the price target from $210 to $153.
08-06 17:47
